ChemoHyperthermia for Non Muscle Invasive Bladder Cancer & unique HIPEC+Agitation. UK company bringing innovative cancer treatments to patients in 40+ countries
We're striving to improve outcomes for NMIBC patients, who account for 70-85% of bladder cancer cases. Our #HIVEC® treatment with mitomycin C has promising results in >100k cases & is now being trialled in the @HIVEC_HEAT phase 3 trial.
#bladdercancerawarenessmonth#CombatCancer
🩸 Blood in your urine is the most common symptom of bladder cancer.
It can appear once or come and go, but it should never be ignored. Early detection makes treatment far more effective.
Feeling unsure? Get checked.
👉 https://t.co/6QJiOk6pHw
#BladderCancerMonth26 #BladderCancer #GetChecked
"Can you put the symptoms and hydration scale on ONE poster for our loos?"
One of our corporate partners asked, so we built it! 🛠️ Equal parts summer hydration & life-saving symptom guide.
Download, print, & protect your team today: 🔗 https://t.co/mLC7SsEdxN
#PeeAware#LookDown
Bladder cancer has historically been removed via transurethral resection (TURBT). New research presented at the 41st @Uroweb Congress shows that en bloc resection is a viable alternative to conventional TURBT for NMIBC.
#bladdercancerawarenessmonth#HIVEC#CombatCancer
Recurrent UTIs may be an under-recognised red flag for bladder cancer, especially in women. A new study found the strongest association within the first 6 months, especially in patients with ≥5 infections.
👉https://t.co/DoeE6DY2XY
#bladdercancerawareness#HIVEC#CombatCancer
Bladder cancer is the 9th most common cancer worldwide, with 610k new cases & 200k deaths pa. Visible blood in urine is one of the most common symptoms. Early diagnosis improves outcomes, with up to 80% survival rate if detected early.
#bladdercancerawareness#HIVEC#CombatCancer
@CR_UK’s latest report on Cancer In The UK shows uptake for bowel cancer screening has risen from below 60% to 65-75%, largely driven by the switch to the faecal immunochemical test (FIT).
#bowelcancerawareness2026#HIPEC#CombatCancer
We’re calling on the Northern Ireland Executive to lower the bowel cancer screening age from 60 to 50. Yesterday we hosted an event at Stormont, bringing together MLAs, healthcare professionals, and people affected by bowel cancer.
Find out more: https://t.co/ga1SaanTc0
A recently identified virus within a common gut bacterium may shed light on a medical puzzle: why Bacteroides fragilis – present in both healthy people and cancer patients – is associated with colorectal cancer.
👉https://t.co/Kir0cj3vFu
#bowelcancerawareness#HIPEC#CombatCancer
👊Final analysis of HIPECT4 phase 3 clinical trial!
Mitomycin-C based #HIPEC delivered via Combat PRS+ reduced peritoneal recurrence in patients with locally advanced colon cancer without increasing toxicity.
👉 https://t.co/ROICS1WNNc
#bowelcancerawareness2026#CombatCancer
Adding #HIPEC (hyperthermic intraperitoneal chemotherapy) with mitomycin C via Combat PRS+ to cytoreductive surgery for locally advanced colorectal cancer significantly reduces the risk of locoregional recurrence.
👉 https://t.co/pTD18bhgkW
#bowelcancerawareness2026#CombatCancer
Combat's PRS+ is helping transform the treatment of colorectal cancer. It's the only #HIPEC system with automatic CO2 agitation, ensuring homogenous drug & thermal distribution throughout the abdominal cavity and peritoneal surfaces for maximum effect.
#bowelcancerawarenessmonth
Our PRS+ peritoneal recirculating treatment optimises #HIPEC delivery. It’s the only HIPEC system with automatic C02 agitation, ensuring homogenous drug & thermal distribution to enhance drug penetration.
#OvarianCancerAwarenessMonth#CombatCancer
A retrospective cohort study highlights better short-term perioperative & postoperative outcomes of laparoscopic surgery for ovarian cancer, but no significant survival benefit compared to open surgery.
👉doi:10.7759/cureus.106112
#ovariancancerawarenessmonth#HIPEC#CombatCancer
Some symptoms of ovarian cancer overlap with IBS, leading to misdiagnosis. Yet most people develop IBS in their 20s & 30s, and onset in women ≥50 years is uncommon. In those with new-onset IBS ≥50 years, ovarian cancer should be suspected.
#ovariancancerawarenessmonth#HIPEC
The most common symptoms of ovarian cancer are:
🔴Persistent and severe bloating
🔴Feeling full quickly and/or loss of appetite
🔴Persistent pelvic or abdominal pain
🔴Needing to urinate more urgently/frequently
#ovariancancerawarenessmonth#ovariancancer#HIPEC#CombatCancer
Glucocorticoid receptor activation regulates key processes in ovarian cancer progression by inducing tumour cell dormancy. Small clusters of dormant tumour cells could survive chemo and reactivate.
👉 https://t.co/LxRXNk7ZYo
#ovariancancerawarenessmonth#HIPEC#CombatCancer